Patients with age-related macular degeneration (AMD) initially may present with distortions in fine visual perception, and disease may be asymptomatic. As the disease develops over time, vision ...

AlgorithmicTypography is a Processing library that enables designers, researchers, and artists to explore parametric typography systems. It generates animated grids of typographic characters whose ...

The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to ...

Creating a space that feels truly good to live in isn’t about following trends or filling rooms with expensive pieces. The most successful interiors balance three essentials: comfort, function, and ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...

Complement-mediated hemolytic uremic syndrome (CM-HUS), commonly referred to as atypical HUS, is a rare thrombotic microangiopathy caused by uncontrolled activation of the alternative complement ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...